

Olaf Ortmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/592620/publications.pdf>

Version: 2024-02-01

56
papers

2,273
citations

393982

19
h-index

214527

47
g-index

127
all docs

127
docs citations

127
times ranked

2806
citing authors

#	ARTICLE	IF	CITATIONS
1	Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1195-1209.	1.2	16
2	Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 719-726.	1.2	6
3	Sedentary behaviour in relation to ovarian cancer risk: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , 2021, 36, 769-780.	2.5	19
4	Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. <i>Oncologist</i> , 2021, 26, e1058-e1065.	1.9	42
5	Addendum to: Peri- and postmenopauseâ€”diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short version. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 1377-1378.	0.8	1
6	Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2035-2045.	1.2	14
7	Use of social service counseling by cancer patients: an analysis of quality assurance data of 6339 breast cancer patients from 13 certified centers in Germany treated between 2015 and 2017. <i>BMC Cancer</i> , 2021, 21, 671.	1.1	5
8	<i>STRN-ALK</i> Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1507-1513.	1.5	5
9	Peri- and postmenopauseâ€”diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short version. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 763-777.	0.8	12
10	Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 715-720.	0.8	9
11	Message from the Editor-in-Chief. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 537-537.	0.8	0
12	Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 875-884.	0.8	36
13	Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1813-1818.	1.2	0
14	Recommendation of adjuvant trastuzumab treatment in HER-2-positive breast cancer patients: insights from quality indicator data collected in certified breast cancer centers in Germany, Italy, Austria, and Switzerland. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 383-388.	0.8	8
15	Adherence to guidelines and benefit of adjuvant radiotherapy in patients with invasive breast cancer: results from a large population-based cohort study of a cancer registry. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1131-1140.	0.8	4
16	Quality control and improvement of cancer care: what is needed? 4th European Roundtable Meeting (ERTM) May 5th, 2017, Berlin, Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1097-1102.	1.2	3
17	Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. <i>Climacteric</i> , 2018, 21, 140-147.	1.1	28
18	Screening-relevant age threshold of 70Âyears and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 119-130.	1.1	29

#	ARTICLE	IF	CITATIONS
19	Hormones and risk of breast and gynecological cancer. <i>Der Gynakologe</i> , 2017, 50, 43-54.	1.0	5
20	Current developments in cancer care: including the patients' perspective" 3rd European Roundtable Meeting (ERTM) June 17, 2016, Berlin, Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 673-676.	1.2	6
21	Message from the Editor-in-Chief. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 137-137.	0.8	0
22	Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro. <i>BMC Cancer</i> , 2016, 16, 951.	1.1	50
23	Message from the Editor-in-Chief. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 445-445.	0.8	0
24	Effects of morcellation on long-term outcomes in patients with uterine leiomyosarcoma. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 825-831.	0.8	8
25	Message from the Editor in Chief. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 1-1.	0.8	2
26	Improving cancer care in Europe: Which institutional health structures might be beneficial and why? 1. European Roundtable Meeting (ERTM), 16th May 2014, Berlin, Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1-4.	1.2	19
27	Die Deutsche Akademie für Gynäkologie und Geburtshilfe (DAGG). <i>Der Gynakologe</i> , 2015, 48, 632-632.	1.0	0
28	Is postmenopausal hormone replacement therapy suitable after a cardio- or cerebrovascular event?. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 213-217.	0.8	9
29	4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 647-658.	1.1	51
30	Message from the Editor in Chief. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 705-706.	0.8	0
31	Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2229-2240.	1.2	11
32	Invasive mole in a perimenopausal woman: a case report and systematic review. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 1193-1199.	0.8	8
33	Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	30
34	Psychosomatic Primary Care in Gynecology – Assessment and Acceptance by Residents for Obstetrics and Gynecology in Germany. <i>Geburtshilfe Und Frauenheilkunde</i> , 2014, 74, 569-573.	0.8	4
35	Message from the Editor-in-Chief. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 1-1.	0.8	0
36	Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines. <i>Maturitas</i> , 2014, 77, 336-343.	1.0	23

#	ARTICLE	IF	CITATIONS
37	Message from the Editor-in-Chief. Archives of Gynecology and Obstetrics, 2014, 290, 397-397.	0.8	0
38	Message from the Editor-in-Chief. Archives of Gynecology and Obstetrics, 2014, 290, 199-199.	0.8	0
39	Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Research and Treatment, 2014, 145, 371-379.	1.1	96
40	Message from Editor-in-Chief. Archives of Gynecology and Obstetrics, 2013, 288, 237-237.	0.8	0
41	Message from new Editor-in-Chief Prof. Olaf Ortmann. Archives of Gynecology and Obstetrics, 2013, 288, 1-2.	0.8	3
42	Ovarian epithelial tumors and reproductive factors: a systematic review. Archives of Gynecology and Obstetrics, 2013, 287, 1187-1204.	0.8	70
43	Message from the Editor-in-Chief. Archives of Gynecology and Obstetrics, 2013, 288, 723-723.	0.8	0
44	Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Research and Treatment, 2013, 139, 539-552.	1.1	449
45	Vaginal Estrogen Therapy for Patients with Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2013, 73, 1017-1022.	0.8	12
46	Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Archives of Gynecology and Obstetrics, 2012, 285, 1397-1402.	0.8	59
47	The Treatment of Climacteric Symptoms. Deutsches Ärzteblatt International, 2012, 109, 316-23; quiz 324.	0.6	25
48	Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treatment Reviews, 2011, 37, 97-104.	3.4	25
49	Hormone therapy in perimenopause and postmenopause (HT). Archives of Gynecology and Obstetrics, 2011, 284, 343-355.	0.8	20
50	OP09.03: Does fetal position in the second trimester fetuses affect nuchal fold values?. Ultrasound in Obstetrics and Gynecology, 2010, 36, 77-77.	0.9	0
51	Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Research and Treatment, 2010, 120, 557-565.	1.1	90
52	Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast, 2009, 18, 2-7.	0.9	14
53	OP10.07: Does fetal growth depend on the duration of in vitro cultivation in IVF/ICSI pregnancies?. Ultrasound in Obstetrics and Gynecology, 2009, 34, 94-94.	0.9	0
54	Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Research and Treatment, 2008, 110, 507-520.	1.1	50

#	ARTICLE	IF	CITATIONS
55	Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. <i>Molecular and Cellular Endocrinology</i> , 2007, 264, 50-60.	1.6	31
56	Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Tj ETQq0 0 0 rgBT / Overlock 10	8.3	805